3.2.5. Modification of Rituximab (RTX)

Anti-CD20 monoclonal antibody Rituximab was modified as previously reported [19]. Briefly, the antibody solution (Mabthera®, 10 mg/mL, Roche Pharma AG, Grenzach-Wyhlen, Germany) was allowed to react at 4 ◦C overnight in 0.1 M NaHCO<sup>3</sup> solution with 20 molar equivalent of TCO–NHS ester dissolved in DMSO followed by size exclusion column purification via PD-10 (GE Healthcare Vienna, Austria) to give RTX–TCO in PBS (2.5 mg/mL).
